Back to discover
Drug

Pridopidine

Late-stage clinical development
ClassDopamine D2 receptor modulator
RxNorm682547ChEMBLCHEMBL596802UNIIHD4TW8S2VK
3
Active clinical trials
D(2) dopamine receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis

Clinical trial2026-07-08Results expected Q1 2028 · ClinicalTrials.gov

HEALEY ALS Platform Trial

Clinical trial2026-06-04Results expected Q3 2027 · ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Huntington's Disease (HD)

Clinical trial2026-06-02Results expected Q2 2028 · ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease

Clinical trial2025-03-12Results posted · ClinicalTrials.gov

HEALEY ALS Platform Trial - Regimen D Pridopidine

Clinical trial2023-08-23Results posted · ClinicalTrials.gov

A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).

Clinical trial2022-02-09Results posted · ClinicalTrials.gov

A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Clinical trial2021-11-19Results posted · ClinicalTrials.gov

A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Clinical trial2021-07-19Results posted · ClinicalTrials.gov

A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)

Clinical trial2020-07-22Terminated · ClinicalTrials.gov

A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)

Clinical trial2018-01-12Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Pridopidine
RxNorm CUI
682547
ChEMBL ID
CHEMBL596802
UNII
HD4TW8S2VK
Primary mechanism
Dopamine D2 receptor modulator

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

D(2) dopamine receptor
DRD2 · P14416
MODULATORDopamine D2 receptor modulator

Clinical trials

10 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
10
registered trials across all phases
LATEST COMPLETION 2024
3
Active studies
3
Recruiting
5
Late-stage (III+)
5
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 10
Phase 11Phase 24Phase 2 / 32Phase 33

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Huntington's Disease (HD)

Not yet recruitingPH IIIPrilenian=4002030

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis

RecruitingPH IIIPrilenian=5002029

HEALEY ALS Platform Trial

RecruitingPH II/IIIKey trialMerit E. Cudkowicz, MDn=1,5002028

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease

CompletedPH IIIPrilenian=4992024

HEALEY ALS Platform Trial - Regimen D Pridopidine

CompletedPH II/IIIMerit E. Cudkowicz, MDn=1632022

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease

CompletedPH IIIPrilenian=4992024

HEALEY ALS Platform Trial - Regimen D Pridopidine

CompletedPH II/IIIMerit E. Cudkowicz, MDn=1632022

A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

CompletedPH IPrilenian=232018

A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).

CompletedPH IIPrilenian=1342018

A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

CompletedPH IIPrilenian=4082016
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials